HCM Hutchison China Meditech Ltd Sponsored ADR

Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences

Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“”) (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief Executive Officer of Chi-Med, will present or participate in the following virtual conferences:

  • The 15th Citi China Investor Conference on Thursday, November 5, 2020; and



  • The “China Summit Survey Results: Where is the "Bridge to Innovation" Headed?” Panel as part of the BioCentury-BayHelix 7th China Healthcare Summit on Monday, November 9, 2020.

Members of the management team will attend the above conferences in one-on-one meetings, and will also attend the following virtual investor conferences at certain times:

  • The Bank of America 2020 China Conference held from November 2 to 13, 2020;



  • The Goldman Sachs Asia Pacific Healthcare Forum held from November 16 to 18, 2020;



  • The 11th Annual Jefferies Global Healthcare Conference held from November 17 to 19, 2020;



  • The Morgan Stanley Asia Pacific Summit held from November 18 to 20, 2020; and



  • The Piper Sandler 32nd Annual Healthcare Conference held from December 1 to 3, 2020.

Further information are available at in the Shareholder Information section under “.”

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

Investor Enquiries 
Mark Lee, Senior Vice President+852 2121 8200
Annie Cheng, Vice President+1 (973) 567 3786
  
Media Enquiries 
Americas – Brad Miles, Solebury Trout+1 (917) 570 7340 (Mobile)

Europe – Ben Atwell / Alex Shaw, FTI Consulting+44 20 3727 1030 / +44 7771 913 902 (Mobile) /

+44 7779 545 055 (Mobile)

Asia – Joseph Chi Lo / Zhou Yi, Brunswick+852 9850 5033 (Mobile), /

+852 9783 6894 (Mobile),
  
Nominated Advisor 
Freddy Crossley / Atholl Tweedie,

Panmure Gordon (UK) Limited
+44 (20) 7886 2500

 

EN
30/10/2020

Underlying

Reports on Hutchison China Meditech Ltd Sponsored ADR

 PRESS RELEASE

HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Tr...

HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO® HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient enrollment of SAFFRON, a global Phase III study of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with epidermal growth factor receptor (“EGFR”)-mutated, MET...

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

HUTCHMED (China) (13 HK): The Promising ATTC Platform And Late-Stage P...

Combined with a robust pipeline and partnership strategy, HUTCHMED expects its ATTC platform to deliver potentially transformative cancer and immunology treatments to patients around the world. The company has also seen smooth R&D progress in its various late-stage programmes, eg Fruquintinib (FRUSICA-2 study), Savolitinib registration studies, Surufatinib for pancreatic cancer, Sovleplenib for ITP and wAIHA, and Fanregratinib in IHCC. HUTCHMED will likely embrace a new wave of new indication/pr...

Carol Dou Xiao Qin ... (+3)
  • Carol Dou Xiao Qin
  • Greater China Research Team
  • Sunny Chen

Greater China Daily: Tuesday, November 4, 2025

Top Stories Strategy | Alpha Picks: November Conviction Calls HSI and MSCI China fell 3.5%/4.0% mom in October, dragged by renewed US-China trade tensions and lack of fresh policy signals from the 4th Plenum. We remain constructive in the medium term but expect further consolidation as uncertainties persist. The best performer among our picks was SELL-rated Li Auto (+21.4% mom). For November, we rotate into oversold names with near-term upside: add AIA, LINK REIT, NAURA, Pinduoduo, PICC P&C and...

 PRESS RELEASE

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Even...

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event — HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action — — Lead candidate HMPL-A251 harnesses a selective PI3K/PIKK inhibitor payload, demonstrating promising preclinical efficacy and safety — — Progress in global and China trials, including FRUSICA-2, SANOVO, surufatinib’s PDAC and fanregratinib’s IHCC studies, advances HUTCHMED’s late-stage pipeline — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHM...

 PRESS RELEASE

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC Int...

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics — First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities — — Unique, highly potent PI3K/PIKK inhibitor payload optimized to exploit antibody-conjugate advantages, with directed delivery and low plasma exposure of free payload — — Preclinical data shows robust antitumor activity with synergistic and bystander killing effects — HONG KONG and SHANGHAI ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch